- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06654752
Trattamento semplificato delle riacutizzazioni polmonari in pediatria (STOP PEDS RCT)
Trattamento semplificato delle riacutizzazioni polmonari in uno studio randomizzato e controllato pediatrico (STOP PEDS RCT)
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.
Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.
The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.
Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:
- Clinic throat swab substudy
- Home throat and nasal swab substudy
- Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Erika Enright
- Numero di telefono: 206-897-1922
- Email: eenright@uw.edu
Luoghi di studio
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Reclutamento
- British Columbia Children's Hospital
-
Investigatore principale:
- Jonathan Rayment, MD
-
Contatto:
- Ronak S Ravandi
- Email: ronak.salamatravandi@bcchr.ca
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 0A4
- Reclutamento
- The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
-
Investigatore principale:
- Felix Ratjen, MD
-
Contatto:
- Claire Crompton
- Email: claire.crompton@sickkids.ca
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Reclutamento
- The Children's Hospital Alabama & University of Alabama at Birmingham
-
Investigatore principale:
- Christopher Fowler, MD
-
Contatto:
- Valerie Tarn
- Numero di telefono: 2056385134
- Email: vtarn@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85713
- Reclutamento
- Tucson Cystic Fibrosis Center
-
Investigatore principale:
- Cori Daines, MD
-
Contatto:
- Elizabeth (Lisa) Ryan
- Email: elizabethryan@arizona.edu
-
-
California
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
-
Investigatore principale:
- Martha McKinney, MD
-
Contatto:
- Ariana Teame, BA
- Email: ateame@chla.usc.edu
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Stanford University
-
Contatto:
- Tina Conti, BSRC, RRT, RRT-NPS, C-NPT
- Email: tconti@stanford.edu
-
Investigatore principale:
- Lori WaiHang Lee, MD
-
San Diego, California, Stati Uniti, 92123
- Non ancora reclutamento
- Rady Children's Hospital at University of California San Diego
-
Contatto:
- Lisa Ramos, CRC
- Email: lramosvallejo@health.ucsd.edu
-
Investigatore principale:
- Kathryn Akong, MD
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- Children's Hospital of Colorado
-
Investigatore principale:
- Jordana Hoppe, MD
-
Contatto:
- Mary Cross
- Email: Mary.Cross@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Children's Healthcare of Atlanta & Emory University
-
Contatto:
- Joy Dangerfield
- Email: jdanger@emory.edu
-
Investigatore principale:
- Ajay Kasi, MD
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
-
Investigatore principale:
- Maria Dowell, MD
-
Contatto:
- Lisa Gallo, CRC
- Numero di telefono: 312-227-2473
- Email: lgallo@luriechildrens.org
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Riley Hospital for Children & Indiana University
-
Contatto:
- Lisa Bendy
- Email: lbendy@iu.edu
-
Investigatore principale:
- D. B. Sanders, MD, MS
-
Contatto:
- Misty Thompson
- Email: misthomp@iu.edu
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa
-
Contatto:
- Mary Teresi
- Email: mary-teresi@uiowa.edu
-
Investigatore principale:
- Anthony Fischer, MD
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins Hospital, Johns Hopkins University
-
Contatto:
- Jamelia Maynard
- Email: jmaynar8@jhmi.edu
-
Investigatore principale:
- Peter Mogayzel, MD, PhD, MBA
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Reclutamento
- Boston Children's Hospital & Harvard University
-
Contatto:
- Monica Ulles
- Email: monica.ulles@childrens.harvard.edu
-
Investigatore principale:
- Gregory Sawicki, MD
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109-5212
- Reclutamento
- University of Michigan Health System
-
Contatto:
- Dawn Kruse
- Email: dmkruse@med.umich.edu
-
Investigatore principale:
- Samya Nasr, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55404
- Reclutamento
- Children's Hospitals and Clinics of Minnesota
-
Investigatore principale:
- Brooke Moore, MD
-
Contatto:
- Danniella Balangoy
- Email: Danniella.Balangoy@childrensmn.org
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- The Minnesota Cystic Fibrosis Center & University of Minnesota
-
Investigatore principale:
- Samuel Goldfarb, MD
-
Contatto:
- Alyssa Perry
- Email: ahperry@umn.edu
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- Children's Mercy Hospital
-
Contatto:
- Jana Lomonte
- Email: jblomonte@cmh.edu
-
Investigatore principale:
- Hugo Escobar, MD
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- St. Louis Children's Hospital & Washington University School of Medicine
-
Investigatore principale:
- Jessica Pittman, MD
-
Contatto:
- Taylor Haas, RN, BSN
- Email: koenigt@wustl.edu
-
-
New York
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester Medical Center Strong Memorial
-
Contatto:
- Barbara Johnson, RN
- Email: Barbara_johnson@urmc.rochester.edu
-
Investigatore principale:
- Matthew McGraw, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Reclutamento
- University of North Carolina at Chapel Hill
-
Investigatore principale:
- Jennifer Goralski, MD
-
Contatto:
- Caroline Flowers, CRC
- Email: caroline_flowers@med.unc.edu
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Investigatore principale:
- Gary McPhail, MD
-
Contatto:
- Sharon Donnelly, RN, BSN, CPN
- Email: sharon.kadon@cchmc.org
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239-3098
- Reclutamento
- Oregon Health & Science University
-
Contatto:
- Pierce Nusbaum
- Email: nusbaum@ohsu.edu
-
Investigatore principale:
- Kelvin MacDonald, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Children's Hospital of Philadelphia & University of Pennsylvania
-
Investigatore principale:
- Clement Ren, MD, MBA
-
Contatto:
- Matthew Gari
- Email: garim@chop.edu
-
Contatto:
- Erin Donnelly
- Email: donnellye4@chop.edu
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Reclutamento
- Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
-
Investigatore principale:
- Daniel Weiner, MD
-
Contatto:
- Tyler Johnston, RN
- Email: ateame@chla.usc.edu
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Investigatore principale:
- Sylvia E Szentpeter, MD
-
Contatto:
- Anushka Phadke, CRC
- Numero di telefono: 843-792-4656
- Email: phadke@musc.edu
-
Contatto:
- Sarah Shine, CRC
- Numero di telefono: 843-792-1221
- Email: shinesa@musc.edu
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- Reclutamento
- University of Texas Southwestern & Children's Health
-
Investigatore principale:
- Preeti Sharma, MD
-
Contatto:
- Lindsay Allen, CRC
- Email: Lindsay.Allen@utsouthwestern.edu
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Texas Children's Hospital & Baylor College of Medicine
-
Investigatore principale:
- Fadel Ruiz, MD
-
Contatto:
- Mayel Yepez
- Email: Mayel.YepezDonado@bcm.edu
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05401
- Reclutamento
- Vermont Children's Hospital & University of Vermont Medical Center
-
Investigatore principale:
- Thomas Lahiri, MD
-
Contatto:
- Zachary Dichard
- Email: Zachary.Dichard@uvmhealth.org
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- Virginia Commonwealth University
-
Contatto:
- Aleksander Subotic, CRC
- Email: aleksandar.subotic@vcuhealth.org
-
Investigatore principale:
- Michael T. Schechter, MD
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Reclutamento
- Seattle Children's Hospital
-
Investigatore principale:
- Margaret Rosenfeld, MD
-
Contatto:
- Marissa Nelson, CRC
- Numero di telefono: 206-987-3921
- Email: marissa.nelsen@seattlechildrens.org
-
Contatto:
- Elizabeth Gore, RN, MPH
- Numero di telefono: 206-987-3317
- Email: Liz.Gore@seattlechildrens.org
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- University of Wisconsin
-
Investigatore principale:
- Hara Levy, MD
-
Contatto:
- Nikki Cole, BS, RRT, CCRC
- Email: ndondlinger@wisc.edu
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Children's Wisconsin & Medical College of Wisconsin
-
Investigatore principale:
- Nicholas Antos, MD
-
Contatto:
- Laura Robertson, CCRC
- Email: lrobertson@mcw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Age
- For main cohort and non-HEMT cohort: age 6 to <19 years
- For preschool cohort: age 3 to <6 years
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- sweat chloride ≥ 60 mEq/liter
- two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
-
Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study
-
Highly Effective Modulator Therapy
- For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
- For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
-
For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry
-
For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations
-
Ability to receive text messages and access the internet
Exclusion Criteria:
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
- Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
- Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
- History of solid organ transplant
- History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
- Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
- Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
- Treatment with chronic oral antibiotics other than azithromycin at enrollment
- Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Immediate Antibiotics
Increased airway clearance plus early initiation of oral antibiotics |
Increase airway clearance and start 14 days of preselected oral antibiotics right away |
|
Sperimentale: Tailored Therapy
Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve |
Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
One-year change in pulmonary function by spirometry-measured ppFEV1
Lasso di tempo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease. |
1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
One-Year change in pulmonary function by LCI
Lasso di tempo: 1 year
|
Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level. |
1 year
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recovery to baseline by ppFEV1 and CRISS following a PEx
Lasso di tempo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Recovery to baseline by Lung Clearance Index (LCI)
Lasso di tempo: 28 days
|
Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Safety Endpoint 1: Cumulative oral antibiotic exposure
Lasso di tempo: 1 year
|
Compare cumulative oral antibiotic exposure in each treatment arm. |
1 year
|
|
Safety Endpoint 2: Number of respiratory illnesses
Lasso di tempo: 1 year
|
Compare the number of respiratory illnesses reported over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Lasso di tempo: 28 days
|
Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm. |
28 days
|
|
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Lasso di tempo: 1 year
|
Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm. |
1 year
|
|
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Lasso di tempo: 28 days
|
Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm. |
28 days
|
|
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Lasso di tempo: 1 year
|
Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm. |
1 year
|
|
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Lasso di tempo: 1 year
|
Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm. |
1 year
|
|
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Lasso di tempo: 1 year
|
Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm. |
1 year
|
|
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Lasso di tempo: 1 year
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm. |
1 year
|
|
Qualitative Assessment 1: Caregivers' experience managing study treatment
Lasso di tempo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Qualitative Assessment 2: Study treatment impact on child and family daily life
Lasso di tempo: 1 year
|
To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences. |
1 year
|
|
Health care costs 1: Total estimated cost of antibiotics
Lasso di tempo: 1 year
|
Compare total estimated cost of antibiotics used over the course of the study between treatment arms. |
1 year
|
|
Health care costs 2: Health care utilization
Lasso di tempo: 1 year
|
Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits. |
1 year
|
|
Health care costs 3: Parent work productivity measures (WPAI)
Lasso di tempo: 1 year
|
To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment. |
1 year
|
|
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Lasso di tempo: 28 days
|
Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx). |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Lasso di tempo: 28 days
|
Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Lasso di tempo: 28 days
|
Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Lasso di tempo: 28 days
|
Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Lasso di tempo: 28 days
|
Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Lasso di tempo: 28 days
|
Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Lasso di tempo: 28 days
|
Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Lasso di tempo: 28 days
|
Measure the proportion of approached patients that enrolls. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Lasso di tempo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Lasso di tempo: 28 days
|
Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm. |
28 days
|
|
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Lasso di tempo: 28 days
|
Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm. |
28 days
|
|
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Lasso di tempo: 1 year
|
Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms. |
1 year
|
|
Clinic Throat Swab Substudy 2: Microbiota Measures
Lasso di tempo: 1 year
|
Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments. |
1 year
|
|
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Lasso di tempo: 28 days
|
Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis. |
28 days
|
|
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Lasso di tempo: 28 days
|
Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx). |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Lasso di tempo: 28 days
|
Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Lasso di tempo: 28 days
|
Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28. |
28 days
|
|
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Lasso di tempo: 28 days
|
Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment. |
28 days
|
|
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Lasso di tempo: 28 days
|
Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy. |
28 days
|
|
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Lasso di tempo: 28 days
|
Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study. |
28 days
|
|
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Lasso di tempo: 14 days
|
Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study. |
14 days
|
|
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Lasso di tempo: 28 days
|
Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28). |
28 days
|
|
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Lasso di tempo: 28 days
|
Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state. |
28 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Lasso di tempo: 14 days
|
Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Lasso di tempo: 14 days
|
Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Lasso di tempo: 14 days
|
Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Lasso di tempo: 14 days
|
Describe changes in sleep time from Day 0 to 14 of the exacerbation state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Lasso di tempo: 14 days
|
Compare changes in resting HR to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Lasso di tempo: 14 days
|
Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Lasso di tempo: 14 days
|
Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Lasso di tempo: 14 days
|
Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Lasso di tempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Lasso di tempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Lasso di tempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
|
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Lasso di tempo: 14 days
|
Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms. |
14 days
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
- Investigatore principale: D. B. Sanders, MD, MS, Indiana University
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STOP PEDS RCT
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .